Roche en route to first continuous delivery treatment for nAMD in Europe
CE mark for Contivue platform supports its ambitions for Susvimo in age-related macular degeneration (AMD).
List view / Grid view
CE mark for Contivue platform supports its ambitions for Susvimo in age-related macular degeneration (AMD).
Significant investment in advanced technologies Is expected to support global adoption of mass spectrometry in the next five years.
European Parliament's SANT Committee urges for greater control on medicine provisions to help strengthen security of supply.
First-of-its-kind case continues EMA and MHRA harmonisation, streamlining the global biosimilar approval pathway.
And Eli Lilly and Company’s new oral GLP-1 obesity therapy orforglipron shines in late-phase clinical trials.
The Route B notification pilot will expand the MHRA’s risk-proportionate approach and help prepare for a new modifications process under upcoming regulations.
US regulator says the move to open up the FAERS database will help modernise its safety monitoring.
While no other country has an identical scheme, analysis of the 2025 payment rate shows the UK is significantly behind comparable countries.
The paper explores recent guidance by the EMA and aims to help companies ensure their developments are efficient and effective for the forthcoming transition.
The drug is the first treatment for desmoid tumours to be approved in the region.
Disruption to traditional distribution channels is anticipated to hinder widespread adoption of the channel.
The EMA’s decision permits WuXi Biologics to progress with commercial manufacturing of a global client’s innovative biologic.
In this article, Miguel Angel Ortega Sánchez of ROIS explores how the industry is adapting to new delivery formats, device bottlenecks, and strategic partnership models — and why flexibility, compliance, and tech transfer agility are now critical to success.
Becomes the first monoclonal antibody for the condition to be approved by the MHRA and advances the pharma company’s ambitions in diabetes.
15 August 2025 | By Bruker Microbiology & Infection Diagnostics
This webinar explores the benefits of accelerated microbial identification using MALDI-TOF in pharmaceutical contamination control strategies.